LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "ropeg" as a keyword



A pharmacovigilance study of adverse events associated with polycythemia vera treatments using the FDA Adverse Event Reporting System (FAERS) database

Sign Up to like & get
recommendations! Published in 2025 at "Annals of Hematology"

DOI: 10.1007/s00277-025-06480-1

Abstract: Cytoreductive therapies remain vital to the management of polycythemia vera (PV). Real-world data are needed to complement clinical trial safety information. We evaluated the safety profiles of four commonly used PV therapies—ropeginterferon alfa-2b (ropeg, on-label),… read more here.

Keywords: ropeg; peg ifn; ruxolitinib; adverse event ... See more keywords

Treatment Patterns of Ropeginterferon Alfa-2b-Njft in the Real-World Setting

Sign Up to like & get
recommendations! Published in 2024 at "Blood"

DOI: 10.1182/blood-2024-206228

Abstract: Introduction Ropeginterferon alfa-2b-njft (ropeg) was approved for the treatment of Polycythemia Vera (PV) in US since November 2021. The National Comprehensive Cancer Network (NCCN) guidelines recently recommend ropeg as the preferred cytoreductive regimen in the… read more here.

Keywords: ropeg; treatment; real world; lot ... See more keywords

Prospective Ropeginterferon Alfa-2b Therapy in PV & ET Influences Prothrombotic, Inflammatory and Hypoxia Inducible Factors Activities and Effect of Concomitant DNMT3A Mutation

Sign Up to like & get
recommendations! Published in 2024 at "Blood"

DOI: 10.1182/blood-2024-211716

Abstract: Ropeg-interferon alfa 2b (Ropeg) is FDA-approved for Polycythemia Vera (PV) and used for Essential Thrombocythemia (ET) (Abu-Zeinah 2021; Kiladjian 2022). It targets JAK2V617F-positive cells and normalizes blood counts (Verger 2018). Its effects on PV and… read more here.

Keywords: ropeg; dnmt3a mutation; achieved chr; chr ... See more keywords

Ropeginterferon Alfa-2b Induces High Rates of Clinical, Hematological and Molecular Responses in Polycythemia Vera: Two-Year Results from the First Prospective Randomized Controlled Trial

Sign Up to like & get
recommendations! Published in 2017 at "Blood"

DOI: 10.1182/blood.v130.suppl_1.320.320

Abstract: Background: Interferon-alpha (IFNa) based therapies have been successfully used in myeloproliferative neoplasms (MPN) for over thirty years. Ropeginterferon alfa-2b (Ropeg) is a novel mono-pegylated IFNa, which is administered once every 2 weeks, or monthly during… read more here.

Keywords: bat; treatment; year; research funding ... See more keywords

Ethnic sensitivity analyses of pharmacokinetics, efficacy and safety in polycythemia vera treatment with ropeginterferon alfa-2b

Sign Up to like & get
recommendations! Published in 2024 at "Frontiers in Pharmacology"

DOI: 10.3389/fphar.2024.1455979

Abstract: Ropeginterferon alfa-2b (Ropeg) is approved for the treatment of adults with polycythemia vera (PV). This report aims to analyze the ethnic sensitivity of Ropeg for the treatment of PV, comparing the pharmacokinetics (PK), efficacy, and… read more here.

Keywords: ropeg; treatment; ropeginterferon alfa; efficacy safety ... See more keywords